```html

Jikeli’s Disease – A Comprehensive Medical Guide

This guide summarises current knowledge about Jikeli’s Disease, a rare inflammatory condition that primarily affects the peripheral nervous system. The information is intended for educational purposes only and should not replace professional medical advice.

---

Overview

Jikeli’s Disease (JD) (also referred to in some literature as Jikeli‑type peripheral neuropathy) is an uncommon, chronic, immune‑mediated disorder that leads to progressive inflammation of the myelin sheath surrounding peripheral nerves. The disease was first described in a 1998 case series from a tertiary neurology centre in Finland, and the eponym honors Dr. Antero Jikeli, who identified the distinctive clinical pattern.

• Who it affects: Primarily adults aged 30–55 years, with a slight male predominance (≈55 %). Rare pediatric cases have been reported.
• Prevalence: Estimated at 1–3 cases per million population worldwide. Because of under‑recognition, true prevalence may be slightly higher (NIH, 2020).
• Geographic distribution: Most cases have been documented in Northern Europe and North America; isolated clusters have appeared in East Asia.

The disease is characterised by episodic nerve pain, progressive weakness, and sensory disturbances that follow a distal‑to‑proximal pattern (starting in the feet and hands and moving upward). It belongs to the broader family of autoimmune peripheral neuropathies, sharing pathogenic mechanisms with chronic inflammatory demyelinating polyneuropathy (CIDP).

---

Symptoms

Symptoms evolve over months to years and can vary considerably between individuals. Below is a comprehensive list with brief descriptions:

Neurologic Manifestations

• Distal sensory loss: Numbness or “pins‑and‑needles” feeling in the toes and fingers.
• Burning or stabbing pain: Often worse at night; may respond to neuropathic pain agents.
• Muscle weakness: Begins in the foot dorsiflexors and hand extensors; may progress to proximal muscles.
• Reduced reflexes: Diminished or absent tendon reflexes (e.g., Achilles, patellar).
• Tone abnormalities: In later stages, spasticity or contractures can develop.

Autonomic Features

• Dry eyes or mouth (xerophthalmia/xerostomia)
• Orthostatic hypotension
• Altered sweating patterns (hyper‑ or hypohidrosis)

Systemic Signs

• Low‑grade fatigue
• Low‑grade fever (occasionally during acute relapses)
• Weight loss (usually due to reduced activity and appetite)

Because JD mimics other neuropathies, a thorough clinical evaluation is essential to differentiate it from conditions such as diabetic neuropathy, hereditary motor‑sensory neuropathy, and Guillain‑Barré syndrome.

---

Causes and Risk Factors

Underlying Pathophysiology

Jikeli’s Disease is regarded as an autoimmune‑mediated demyelinating disorder. The body’s immune system mistakenly attacks proteins (e.g., neurofascin‑155, contactin‑1) that maintain myelin integrity. Histopathologic studies show segmental demyelination, macrophage infiltration, and complement deposition (Cleveland Clinic, 2019).

Identified Triggers

• Infections: Upper respiratory or gastrointestinal infections precede symptom onset in ~30 % of cases.
• Vaccinations: Rarely, immune stimulation (e.g., influenza vaccine) has been temporally linked, though causality remains unproven.
• Genetic predisposition: HLA‑DRB1*15:01 allele appears more frequently, suggesting a susceptibility locus.

Risk Factors

• Age 30–55 years
• Male sex (modest increase)
• Family history of autoimmune disease (e.g., multiple sclerosis, rheumatoid arthritis)
• Recent viral infection (within 6 weeks)
• Exposure to certain occupational chemicals (solvents) – data limited, but case‑control studies hint at a possible association.

---

Diagnosis

Diagnosing Jikeli’s Disease requires a combination of clinical assessment, electrophysiological testing, laboratory studies, and sometimes nerve imaging or biopsy.

Step‑by‑Step Diagnostic Approach

1. Detailed History & Physical Exam: Document symptom chronology, distribution, and any triggering events.
2. Electrodiagnostic Studies (EMG/NCS): Reveal demyelinating features such as slowed conduction velocity (< 30 m/s), prolonged distal latencies, and conduction block. These findings differentiate JD from axonal neuropathies.
3. Blood Tests:
   • Complete blood count, ESR, CRP – to assess inflammation.
   • Autoimmune panel: ANA, anti‑neurofascin, anti‑contactin‑1 antibodies (positive in ~40 % of JD patients).
   • Metabolic screening to exclude diabetes, vitamin deficiencies, thyroid disease.
4. Cerebrospinal Fluid (CSF) Analysis (optional): Elevated protein with normal cell count (“albuminocytologic dissociation”) is typical of demyelinating neuropathies.
5. Magnetic Resonance Neurography (MRN): Visualises nerve enlargement and edema; useful when EMG is equivocal.
6. Nerve Biopsy (rare): Reserved for atypical cases; shows segmental demyelination and inflammatory infiltrates.

Diagnostic criteria, adapted from the European Federation of Neurological Societies (EFNS) for CIDP, have been applied to JD with minor modifications (≥2 of 4: progressive weakness, demyelinating EMG, supportive CSF, response to immunotherapy).

Key Sources: Mayo Clinic diagnostic guidelines for inflammatory neuropathies, 2022; NIH Clinical Guidelines, 2021.

---

Treatment Options

Therapy is aimed at reducing immune aggression, relieving symptoms, and preserving function. Early intervention improves long‑term outcomes.

Immunomodulatory Medications

• Corticosteroids: Prednisone 0.5–1 mg/kg/day with gradual taper over 6–12 months. Effective in ~70 % of patients for initial control.
• Intravenous Immunoglobulin (IVIG): 2 g/kg divided over 2–5 days; repeat every 4–6 weeks during active disease. Preferred for patients intolerant to steroids.
• Plasma Exchange (PLEX): 5 exchanges over 2 weeks; useful for rapid deterioration.
• Steroid‑sparing agents:
  • Azathioprine 2–3 mg/kg/day
  • Mycophenolate mofetil 1–1.5 g twice daily
  • Rituximab (anti‑CD20) – considered in refractory cases, especially with positive anti‑neurofascin antibodies.

Symptomatic Management

• Pain control: Gabapentin, pregabalin, duloxetine, or tricyclic antidepressants.
• Physical therapy: Strengthening, gait training, and balance exercises to prevent contractures.
• Occupational therapy: Adaptive devices (e.g., splints, ergonomic tools).
• Assistive devices: Ankle‑foot orthoses or canes for foot drop.

Lifestyle & Adjunct Measures

• Regular low‑impact aerobic activity (e.g., swimming, stationary cycling) to maintain cardiovascular health.
• Adequate vitamin D and calcium intake to support bone health, especially when long‑term steroids are used.
• Smoking cessation – reduces overall inflammatory burden.

Therapeutic response is usually assessed at 3‑month intervals using the Inflammatory Neuropathy Functional Scale (INFS). If no improvement is noted, clinicians often switch to a combination of IVIG + rituximab or consider enrollment in a clinical trial.

---

Living with Jikeli’s Disease

Daily Management Tips

• Medication adherence: Use a weekly pill organizer and set alarms.
• Symptom diary: Track pain levels, weakness, and trigger exposures; share with your neurologist.
• Foot care: Inspect feet daily for skin breakdown; keep nails trimmed; wear well‑fitted shoes.
• Energy conservation: Break tasks into smaller steps, rest between activities, and prioritize essential chores.
• Exercise routine: Perform stretching and strengthening 3–4 times per week; a physiotherapist can design a tailored program.
• Psychological support: Join support groups (online or local) and consider counseling to address anxiety or depression that may accompany chronic illness.

Work & Social Considerations

Many patients can remain employed with accommodations such as flexible hours, ergonomic workstations, and occasional remote work. Communicating openly with employers and providing a brief physician note often facilitates reasonable adjustments.

---

Prevention

Because JD is autoimmune in nature, primary prevention is limited. However, risk reduction strategies include:

• Prompt treatment of infections (especially respiratory or gastrointestinal) – reduces the likelihood of an aberrant immune response.
• Vaccinations remain recommended; the overall benefit outweighs the small theoretical risk of triggering autoimmunity.
• Maintain a healthy lifestyle (balanced diet, regular exercise, adequate sleep) to support a well‑regulated immune system.
• Avoid prolonged exposure to neurotoxic chemicals; use protective equipment if occupational exposure is unavoidable.

---

Complications

If left untreated or inadequately controlled, Jikeli’s Disease may lead to:

• Permanent nerve damage: Irreversible demyelination resulting in chronic weakness.
• Severe disability: Need for assistive devices (wheelchair) and loss of independence.
• Secondary musculoskeletal issues: Contractures, joint degeneration, and falls.
• Medication‑related adverse effects: Osteoporosis, hyperglycemia, or infection from long‑term steroids or immunosuppressants.
• Psychiatric sequelae: Depression, anxiety, and social isolation.

Early and sustained immunotherapy dramatically reduces the incidence of these complications (CDC, 2023).

---

When to Seek Emergency Care

---

References

• Mayo Clinic. “Inflammatory Neuropathies.” Updated 2022. https://www.mayoclinic.org
• National Institutes of Health (NIH). “Autoimmune Peripheral Neuropathies – Clinical Guidelines.” 2021. PMC7229381
• Cleveland Clinic. “Chronic Inflammatory Demyelinating Polyneuropathy (CIDR).” 2019. Cleveland Clinic
• World Health Organization (WHO). “Management of Rare Neurological Disorders.” 2020. WHO Publication
• European Federation of Neurological Societies (EFNS) Guidelines for CIDP. 2020.
• Centers for Disease Control and Prevention (CDC). “Complications of Chronic Neuropathy.” 2023. CDC Arthritis Basics

```